Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.
first published: Oct 25, 2013 11:56 am
A collection of the most-viewed Moneycontrol videos.
Nifty Poised To Clock Weekly Gains; PSU Banks & Metals Star Performers This Week| Closing Bell Live
WeWork India’s Rs 3,000 Cr IPO Kicks Off| MD & CEO Karan Virwani On Future Roadmap| IPO Watch Live
Nifty Set To End Week Strong As Bulls Charge Towards 25,000 | Opening Bell Live
Nifty Zooms Past 24,800 As RBI Policy Revives Festive Cheer| Banks Top Gainers| Closing Bell Live
You are already a Moneycontrol Pro user.